Coherus Oncology, Inc. CHRS
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -11.96% | -- | -- | -- | -302.24% |
| Total Depreciation and Amortization | -0.63% | -- | -- | -- | -22.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -115.71% | -- | -- | -- | 169.66% |
| Change in Net Operating Assets | -1,378.69% | -- | -- | -- | -90.71% |
| Cash from Operations | -214.06% | -- | -- | -- | -9.15% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 44.39% | -- | -- | -- | -105.69% |
| Cash from Investing | 44.39% | -- | -- | -- | -105.56% |
| Total Debt Issued | -- | -- | -- | -- | -100.38% |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | 25,589.21% | -- | -- | -- | -98.34% |
| Repurchase of Common Stock | 59.51% | -- | -- | -- | 90.40% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 987.50% | -- | -- | -- | -100.04% |
| Cash from Financing | 31,008.50% | -- | -- | -- | 99.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -73.98% | -- | -- | -- | -189.21% |